Naltrexone augmentation in OCD: a double-blind placebo-controlled cross-over study.
about
Citalopram versus other anti-depressive agents for depressionDrug treatment of obsessive-compulsive disorderCanadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disordersPathologic skin picking.Obsessive-compulsive disorder, impulse control disorders and drug addiction: common features and potential treatments.Compulsive features in behavioural addictions: the case of pathological gamblingOpioids and anxiety.Pharmacological management of treatment-resistant obsessive-compulsive disorder.Pharmacotherapy of obsessive-compulsive disorder: evidence-based treatment and beyond.Augmentation strategies in obsessive-compulsive disorder.Pharmacological, experimental therapeutic, and transcranial magnetic stimulation treatments for compulsivity and impulsivity.Emerging drugs to treat obsessive-compulsive disorder.Comorbidity of obsessive-compulsive disorder and substance use disorder: a new heuristic.DSM-5 obsessive-compulsive and related disorders: clinical implications of new criteria.Pharmacologic treatment of obsessive-compulsive disorder comorbidity.Unpacking the role of self-reported compulsivity and impulsivity in obsessive-compulsive disorder.Investigating the role of anticipatory reward and habit strength in obsessive-compulsive disorder.
P2860
Q24202141-E4934D62-C9A6-4BC1-830F-7560F70AFE43Q24635508-69B33901-E5D3-45B0-A8BC-09C364B67D97Q27009995-066095ED-6994-4C5B-B243-6225E0CC3F51Q34022868-30A56B28-889A-42C8-9F20-B13483F40184Q34184771-8DB82216-8E09-4D8D-84B0-AE3477B5CDA9Q35670338-009ADB5A-1530-4E3E-9507-01BF304B8D81Q37763407-091A55C6-4226-4BF8-A0D8-B98769A47141Q37893636-FC1B8C5A-7063-4ABA-BB44-2C98CC4718A6Q38057736-378C7FB1-D9CF-4D1C-9A59-AE1CF62A8EC7Q38078029-80D11268-395C-4209-98EC-180AB0CA4AB4Q38157123-7392C58A-E6BF-4C6E-A4CE-B94D567B6A0FQ38174649-943CF778-D25E-4C04-87ED-7933888FE6CCQ38178524-89E6681F-E31E-4945-B5EB-E7CD6EBA63D4Q38194998-8D3F562B-96C1-4671-9197-2DDC3E106C2DQ38254003-643F9A94-77E5-40A6-ABE8-A7EA43CD786AQ38795479-944ED8FF-7F39-49A6-B085-2BB905E32597Q47834747-54C1D026-D626-4DB2-A5BD-2BBBA1863083
P2860
Naltrexone augmentation in OCD: a double-blind placebo-controlled cross-over study.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Naltrexone augmentation in OCD: a double-blind placebo-controlled cross-over study.
@en
Naltrexone augmentation in OCD: a double-blind placebo-controlled cross-over study.
@nl
type
label
Naltrexone augmentation in OCD: a double-blind placebo-controlled cross-over study.
@en
Naltrexone augmentation in OCD: a double-blind placebo-controlled cross-over study.
@nl
prefLabel
Naltrexone augmentation in OCD: a double-blind placebo-controlled cross-over study.
@en
Naltrexone augmentation in OCD: a double-blind placebo-controlled cross-over study.
@nl
P2093
P1476
Naltrexone augmentation in OCD: a double-blind placebo-controlled cross-over study
@en
P2093
Ari Gershon
Joseph Zohar
Revital Amiaz
P304
P356
10.1016/J.EURONEURO.2008.01.006
P407
P50
P577
2008-03-18T00:00:00Z